WEE1 and cancer: However, there are 29 clinical trials with the WEE1 inhibitor MK1775 (also known as AZD1775), which test its ability to impair alone or in combination with other cytostatic drugs (e.g., cisplatin, paclitaxel, 5-fluorouracil, and topotecan) the growth of different kinds of cancer (Table S1).